What is HC Wainwright’s Forecast for BLFS Q1 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for BioLife Solutions in a research note issued on Monday, November 18th. HC Wainwright analyst Y. Chen forecasts that the medical equipment provider will post earnings per share of ($0.10) for the quarter. HC Wainwright currently has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.41) EPS.

Several other research analysts have also recently issued reports on BLFS. TD Cowen raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Craig Hallum lifted their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Northland Securities lifted their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

BioLife Solutions Trading Up 1.5 %

BLFS stock opened at $25.39 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions has a one year low of $11.91 and a one year high of $28.88. The company has a market capitalization of $1.18 billion, a PE ratio of -23.95 and a beta of 1.88. The company’s 50 day moving average price is $23.96 and its two-hundred day moving average price is $22.88.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the transaction, the executive now owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Aby J. Mathew sold 17,604 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the transaction, the executive vice president now directly owns 284,442 shares of the company’s stock, valued at $5,703,062.10. This represents a 5.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,644 shares of company stock valued at $1,527,503. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently modified their holdings of BLFS. Mark Sheptoff Financial Planning LLC purchased a new position in shares of BioLife Solutions in the 3rd quarter worth about $28,000. 1620 Investment Advisors Inc. purchased a new position in shares of BioLife Solutions in the 2nd quarter worth about $35,000. Isthmus Partners LLC raised its position in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 42,265 shares during the last quarter. Quest Partners LLC purchased a new position in shares of BioLife Solutions in the 3rd quarter worth about $57,000. Finally, GAMMA Investing LLC raised its position in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.